GSK: intends to defend itself 'vigorously' over Zantac

(CercleFinance.com) - GSK said on Thursday it would defend itself "vigorously" against the complaints filed in the US as part of the litigation over the stomach acid drug Zantac, which it was the first to market in the US in the 1980s.


In a statement issued last night, the British pharmaceutical company said it acknowledges the filing of some 3,000 claims in several federal and state courts by patients linking their cancer to Zantac.

GSK stresses that its work, like that of the FDA or the European Medicines Agency, has not shown any direct causality between the intake of ranitidine, one of the ingredients of Zantac, and the development of cancer.



Copyright (c) 2022 CercleFinance.com. All rights reserved.